Voyageur Pharmaceuticals Announces Completion of Shares for Debt Settlement

Voyageur Pharmaceuticals Ltd. (VM) completed the issuance of 1,240,644 common shares to settle $192,300 in outstanding indebtedness. The shares were issued at a deemed price of $0.155 per share, with 337,419 shares allocated to a related-party officer for $52,300 in accrued consulting fees, and 903,225 shares to other creditors for $140,000.

The transaction was structured to preserve the company's limited cash position and received final acceptance from the TSX Venture Exchange. Issued shares carry a four-month and one-day hold period. The move follows a similar $100,000 debt settlement in April 2026 and aligns with the company's ongoing efforts to manage liquidity while advancing feasibility studies.

Voyageur Pharmaceuticals Ltd. (VM) settled a dispute for $192,300, an amount considered immaterial relative to the company’s approximately $25 million market capitalization and its recent $5 million equity raise. The transaction resulted in expected dilution, a consequence of the company’s explicit going concern warning and a cash balance of $75,709 as of Q1 2026.

The settlement does not alter the fundamental development timeline or strategic roadmap. It is characterized as a routine liquidity management action consistent with prior debt settlements and the company's pre-revenue status. The move was fully in line with market expectations for a cash-constrained junior, generating no material positive or negative surprise.

Voyageur Pharmaceuticals Ltd. (VM) is a pre-revenue Canadian junior focused on building a vertically integrated North American supply chain for radiology contrast media. The company’s flagship projects include the Frances Creek barite project in British Columbia and a collaborative iodine extraction initiative in Oklahoma with Bayer AG.

Voyageur utilizes the proprietary Mueller iodine extraction process to produce high-purity iodine from oilfield brine, aiming to bypass traditional flake processing. Regulatory progress includes Health Canada-approved barium contrast products and an active FDA 505(b)(2) submission for barium agents initiated in February 2026. The company’s strategic goal is to become the first fully integrated producer of both barium and iodine contrast agents in North America, targeting 1,000 tonnes/year of iodine production capacity.